A patient implanted with OrbusNeich Medical Inc.’s Genous Bio-engineered R stents showed 100 percent strut and complete neotintimal coverage 26 days after the procedure, the company said.*
The patient, a 62-year-old male, received two 2.5 mm diameter models of the stents after doctors diagnosed an anterior ST-elevation myocardial infarction — a heart attack.
The doctors found the patient to be experiencing acute thrombotic occlusion of the proximal left anterior descending artery, with critical lesions identified in the proximal and mid LAD and a chronic total occlusion of the proximal right coronary artery, according to OrbusNeich.
Researchers announced the findings at the Japanese Assn. of Cardiovascular Intervention and Therapeutics.
“This is the first documentation of complete endothelialization after 26 days of Genous stent implantation, showing the pro-healing effect in vivo,” said Prof. Stephen Wai–Luen Lee, one of the researchers for OrbusNeich’s study.
At the EuroPCR conference in Paris in May, the company announced that 12-month follow-up data from a subset analysis of the global e-HEALING registry demonstrated that the company’s Genous-coated R stent is effective in diabetic patients.